City

Baltimore (1)

New York (1)

Philadelphia (1)

Condition

Refractory Acute Leukemia (2)

Relapsed Acute Leukemia (2)

High-Risk Myelodysplasia (1)

Overall Status

Completed (1)

Terminated (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

Sidney Kimmel Cancer Center at Thomas Jefferson University (1)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Collaborator

Millennium Pharmaceuticals, Inc. (1)

Pfizer (1)

The Leukemia and Lymphoma Society (1)

Intervention

bortezomib 1.0mg/m^2 (1)

bortezomib 1.3mg/m^2 (1)

bortezomib with mitoxantrone, etoposide and cytarabine (1)

pd 0332991 (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

relapsed acute leukemia

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Relapsed Acute Leukemia, Refractory Acute Leukemia Trial in Philadelphia (Bortezomib with mitoxantrone, etoposide and

Completed

Has Results

Relapsed Acute Leukemia
Refractory Acute Leukemia

Bortezomib with mitoxantrone, etoposide and cytarabine
+2 more

Philadelphia, Pennsylvania

Sidney Kimmel Cancer Center at Thomas Jefferson University

Apr 23, 2018

Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia Trial in Baltimore, New York (PD 0332991)

Terminated

Has Results

Relapsed Acute Leukemia
+2 more

PD 0332991

Baltimore, Maryland
+1 more

Aug 30, 2013